advertisement
Yednock T 17
Showing records 1 to 17 | Display all abstracts from Yednock T107667 Pharmacokinetic and Target Engagement Measures of ANX007, an Anti-C1q Antibody Fragment, Following Intravitreal Administration in Nonhuman Primates
Grover A
Investigative Ophthalmology and Visual Science 2023; 64: 3
108538 Safety and Target Engagement of Complement C1q Inhibitor ANX007 in Neurodegenerative Eye Disease: Results from Phase I Studies in Glaucoma
Sun Y; Wirta D
Ophthalmology science 2023; 3: 100290
107667 Pharmacokinetic and Target Engagement Measures of ANX007, an Anti-C1q Antibody Fragment, Following Intravitreal Administration in Nonhuman Primates
Sankaranarayanan S; Sankaranarayanan S
Investigative Ophthalmology and Visual Science 2023; 64: 3
108538 Safety and Target Engagement of Complement C1q Inhibitor ANX007 in Neurodegenerative Eye Disease: Results from Phase I Studies in Glaucoma
Murahashi W
Ophthalmology science 2023; 3: 100290
107667 Pharmacokinetic and Target Engagement Measures of ANX007, an Anti-C1q Antibody Fragment, Following Intravitreal Administration in Nonhuman Primates
Mathur V
Investigative Ophthalmology and Visual Science 2023; 64: 3
108538 Safety and Target Engagement of Complement C1q Inhibitor ANX007 in Neurodegenerative Eye Disease: Results from Phase I Studies in Glaucoma
Mathur V
Ophthalmology science 2023; 3: 100290
107667 Pharmacokinetic and Target Engagement Measures of ANX007, an Anti-C1q Antibody Fragment, Following Intravitreal Administration in Nonhuman Primates
Suri P
Investigative Ophthalmology and Visual Science 2023; 64: 3
108538 Safety and Target Engagement of Complement C1q Inhibitor ANX007 in Neurodegenerative Eye Disease: Results from Phase I Studies in Glaucoma
Sankaranarayanan S
Ophthalmology science 2023; 3: 100290
107667 Pharmacokinetic and Target Engagement Measures of ANX007, an Anti-C1q Antibody Fragment, Following Intravitreal Administration in Nonhuman Primates
Qiu H
Investigative Ophthalmology and Visual Science 2023; 64: 3
108538 Safety and Target Engagement of Complement C1q Inhibitor ANX007 in Neurodegenerative Eye Disease: Results from Phase I Studies in Glaucoma
Sankaranarayanan S
Ophthalmology science 2023; 3: 100290
107667 Pharmacokinetic and Target Engagement Measures of ANX007, an Anti-C1q Antibody Fragment, Following Intravitreal Administration in Nonhuman Primates
Andrews-Zwilling Y
Investigative Ophthalmology and Visual Science 2023; 64: 3
108538 Safety and Target Engagement of Complement C1q Inhibitor ANX007 in Neurodegenerative Eye Disease: Results from Phase I Studies in Glaucoma
Taylor LK; Taylor LK; Yednock T
Ophthalmology science 2023; 3: 100290
107667 Pharmacokinetic and Target Engagement Measures of ANX007, an Anti-C1q Antibody Fragment, Following Intravitreal Administration in Nonhuman Primates
Mease K
Investigative Ophthalmology and Visual Science 2023; 64: 3
108538 Safety and Target Engagement of Complement C1q Inhibitor ANX007 in Neurodegenerative Eye Disease: Results from Phase I Studies in Glaucoma
Yednock T
Ophthalmology science 2023; 3: 100290
107667 Pharmacokinetic and Target Engagement Measures of ANX007, an Anti-C1q Antibody Fragment, Following Intravitreal Administration in Nonhuman Primates
Taylor LK; Taylor LK
Investigative Ophthalmology and Visual Science 2023; 64: 3
108538 Safety and Target Engagement of Complement C1q Inhibitor ANX007 in Neurodegenerative Eye Disease: Results from Phase I Studies in Glaucoma
Fong DS; Goldberg JL
Ophthalmology science 2023; 3: 100290
107667 Pharmacokinetic and Target Engagement Measures of ANX007, an Anti-C1q Antibody Fragment, Following Intravitreal Administration in Nonhuman Primates
Cahir-McFarland E; Keswani S; Yednock T; Yednock T
Investigative Ophthalmology and Visual Science 2023; 64: 3
